As of June 30, 2023, the company had cash and cash equivalents of $5.2 million, compared to $19.9 million as of December 31, 2022. Net cash used in operating activities during the three months ended June 30, 2023 was approximately $7.5 million. The company believes its cash on hand is adequate to fund budgeted operations into the fourth quarter of 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CLRB:
- Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update
- Cellectar Biosciences reports Q2 EPS (73c), consensus ($1.00)
- Cellectar Biosciences Inc (CLRB) Q2 Earnings Cheat Sheet
- Cellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual Meeting
- Cellectar Biosciences presented data at SNMMI on study of iopofosine I 131